Table 3 Study population and treatment group characteristics
Home-based pdC1-INH (N = 20) | Home-based icatibant (N = 11) | Hospital-based pdC1-INH (N = 8) | Overall (N = 39) | |
|---|---|---|---|---|
Gender, N (%) | ||||
Female | 13 (65.0) | 8 (72.7) | 5 (62.5) | 26 (66.6) |
Male | 7 (35.0) | 3 (27.3) | 3 (37.5) | 13 (33.4) |
Age, mean (±SD) | 33.0 (±18.7) | 37.0 (±11.7) | 31.0 (±20.4) | 33.7 (±17.1) |
Disease severity score, mean (±SD) | 7.8 (±1.7) | 6.9 (±1.6) | 6.6 (±1.5) | 7.3 (±1.7) |